Industry

Elecoglipron demonstrated a favorable safety and tolerability profile in Chinese adults living with obesity/overweight with or without type 2 diabetes mellitus (T2DM), consistent with that of the GLP-1 receptor agonist class Pharmacokinetic results in this study were comparable with the prior data generated from global Phase 1 clinical studies, supporting potential use of a consistent … [Read more…]

FOSTER CITY, Calif.–(BUSINESS WIRE)–#Dividend–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 3.8% in the company’s quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on … [Read more…]

GENTILLY, France–(BUSINESS WIRE)–THX Pharma (Theranexus) and Biocodex, an independent international pharmaceutical group, today announced the execution of a strategic licensing agreement to advance the development of two drug candidates in three rare diseases with high unmet medical needs: Batten disease with Batten-1, and Gaucher disease and Niemann-Pick type C disease with TX01. Under the agreement, … [Read more…]

The breakthrough formula starts to repair sensitive areas of teeth after 60 seconds for substantial sensitivity relief in 3 days, delivering long-lasting relief with twice-daily brushing Key Takeaways Sensodyne unveils Clinical Repair, the brand’s newest toothpaste option for sensitive teeth. Clinical Repair: Starts to repair sensitive areas of teeth after 60 seconds* for clinically proven … [Read more…]

Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period CAMBRIDGE, England–(BUSINESS WIRE)–AstraZeneca: Revenue and EPS summary   FY 2025 % Change Q4 2025 % Change   $m Actual CER1 $m Actual CER – Product Sales 55,573 9 9 14,538 9 7 – Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 … [Read more…]

CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, … [Read more…]

– Funding secured, extending the financial runway to reach a proof-of-concept inflection point – Company’s attractiveness reinforced through the onboarding of new investors LILLE, France & PARIS–(BUSINESS WIRE)–4Moving Biotech (4MB), a clinical-stage biotechnology company and a spin-off of 4P-Pharma, developing a first-in-class disease-modifying osteoarthritis drug (DMOAD) for knee osteoarthritis, today announced the closing of a … [Read more…]

  LOS ANGELES–(BUSINESS WIRE)–Consensus Cloud Solutions, Inc. (NASDAQ: CCSI) today reported preliminary financial results for the fourth quarter and year ended December 31, 2025. “I want to congratulate our employees on a year of many accomplishments. We returned to total revenue growth in the last three quarters of the year, driven by our corporate channel … [Read more…]

Conducting Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA), for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV) Introduced New Immunology Program Focused on MRGPRX2 Inhibition; On Track to Select a Development Candidate in 2H 2026 On Track to File an Investigational New Drug Application (IND) … [Read more…]

LEXINGTON, Mass.–(BUSINESS WIRE)–$AGEN #AACRIO—Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted for poster presentation at the American Association for Cancer Research- Immuno-Oncology (AACR-IO) Conference, taking place in Los Angeles, CA on February 18–21, 2026. The abstract, titled … [Read more…]